Corcept Therapeutics Incorporated / Fundamentals
Income statement
- Net revenue
€610.78M - Cost of goods sold
€9.94M - Gross profit
€600.84M - SG&A expenses
€299.92M - R&D expenses
€213.96M - EBITDA
€87.75M - D&A
€1.22M - EBIT
€86.96M - Interest expenses
€0.00 - EBT
€107.65M - Tax expenses
€12.30M - Net income
€113.03M
Cash flow statement
- Net deferred tax
-€43.10M - Non-cash items
-€18.46M - Changes in working capital
€38.75M - Operating cash flow
€155.40M - Capex
€1.64M - Other investing cash flow
€0.00 - Net investing cash flow
-€35.35M - Total cash dividends paid
€0.00 - Issuance of common stock
-€4.20M - Debt repayment
€0.00 - Other financing cash flow
-€55.76M - Net financing cash flow
-€143.63M - Foreign exchange effects
€1.53M - Net change in cash
-€22.04M - Cash at end of period
€87.64M - Free cash flow
€157.04M
Balance sheet
- Cash and cash equivalents
€87.64M - Cash and short-term investments
€291.90M - Total receivables
€55.07M - Inventory
€10.47M - Other current assets
€20.51M - Total current assets
€377.95M - Property, plant & equipment
€6.24M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€147.37M - Other non-current assets
€13.90M - Total non-current assets
€305.88M - Total assets
€683.83M - Accounts payable
€20.07M - Short-term debt
€867.45K - Other current liabilities
€59.07M - Total current liabilities
€123.39M - Long-term debt
€4.77M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€13.37M - Total non-current liabilities
€18.14M - Total liabilities
€141.53M - Common stock
€117.71K - Retained earnings
€511.29M - Other equity
€1.95M - Total equity
€542.30M - Total liabilities and shareholders' equity
€683.83M
Company information
- Market capitalization
€6.62B - Employees
500 - Enterprise Value
€7.47B
Company ratios
- Gross margin
-
98.4% Much better than peer group: -626,247,392,529.2% - EBITDA margin
-
14.4% Much better than peer group: -1,481,388,533,512.7% - EBIT margin
-
14.2% Much better than peer group: -1,566,506,871,970.5% - EBT margin
-
17.6% Much better than peer group: -1,503,243,861,062.0% - Net margin
-
18.5% Much better than peer group: -1,503,243,860,257.9% - ROE
-
20.8% Much worse than peer group: 62.1% - ROA
-
16.5% Much better than peer group: -53.6% - Asset turnover
-
89.3% Much better than peer group: 20.7% - FCF margin
-
25.2% Much better than peer group: -1,252,357,517,296.5% - FCF yield
2.3% - Efficiency ratio
85.6% - Net sales per employee
-
€1.22M - Net income per employee
-
€226.06K